Glaucoma – Current Treatment – Current Treatment: Physician Insights – Glaucoma (EU5)

Glaucoma is a progressive disease of the optic nerve caused by high intraocular pressure (IOP); it is one of the leading causes of vision loss in Europe. Treatment of glaucoma aims to lower and stabilize IOP. Pharmacotherapy is widely used, although nonpharmacological interventions continue to gain traction in the treatment of the major subtype of the disease—primary open-angle glaucoma (OAG). Although the European glaucoma therapy market is crowded and highly genericized, branded therapies play an important role in later lines of treatment. The EMA-approved therapies Rhokiinsa and Roclanda could further expand the treatment armamentarium for OAG if they become available in European markets. Nonpharmacological approaches to treating OAG include incisional glaucoma surgery, selective laser trabeculoplasty (SLT), and devices for micro / minimally invasive glaucoma surgery (MIGS).

Questions answered

• How do treatment approaches differ between mild / moderate OAG and severe disease?
• Which pharmaceutical agents are most often prescribed for OAG?
• How successful are branded therapies such as Simbrinza and Diamox relative to generically available agents?
• Do ophthalmologists expect the EMA-approved therapies Rhokiinsa and Roclanda to play a role in the treatment of glaucoma in the future?
• Which MIGS devices garner the greatest share among primary OAG patients?
• Have data from the LiGHT trial on the use of SLT in early lines of therapy influenced ophthalmologists’ use of this approach?
• How do ophthalmologists envision their treatment of primary OAG evolving over the next three years?

Product description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Markets covered: EU5.

Primary research: Survey of 253 EU5 ophthalmologists.

Key drugs covered: Simbrinza, Diamox, Betoptic, Iopidine, latanoprost, brimonidine, timolol, brinzolamide, Rhokiinsa, and Roclanda.

Key companies: Alcon, Santen, Novartis, AbbVie, Pfizer, and Merck & Co.

Key insights provided

• Factors influencing disease management and treatment decisions.
• Drivers of and constraints on treatment selection.
• Physician-reported treatment practices and brand-level patient shares.
• Rationale for changes in treatment approach.
• Physician insight on persistency and compliance.
• Physician-reported recent / anticipated changes in brand usage over the next three years.